This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Immunomedics Announces Presentations At Upcoming Conferences

Stocks in this article: IMMU

MORRIS PLAINS, N.J., Oct. 10, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that the Company will be making multiple presentations at 3 upcoming scientific and medical conferences.

At the World ADC San Francisco 2013, scheduled for October 14-17, 2013 in San Francisco, CA, Cynthia L. Sullivan, President and Chief Executive Officer, will present "The Growth Potential for using ADCs: Diverse Cancer Types," including the IMMU-130, IMMU-132 and IMMU-110 program descriptions, during the Commercial Leader's Day session on Monday, October 14, at 9:30 a.m. In addition, Dr. David M. Goldenberg, Chairman, Chief Scientific Officer, and Chief Medical Officer, will report "First Clinical Results of SN-38 ADCs in Solid Tumor Therapy" in the Plenary Session: Early Clinical Trial Results on Wednesday, October 16, at 4:30 p.m.

The Company and its collaborators will present 6 studies at the 26 th Annual Congress of the European Association of Nuclear Medicine to be held in Lyon, France, from October 19-23, 2013. The schedule and meeting places for the presentations, together with the abstract number and session title, are listed below:

  • "Preclinical evaluation of Al 18F- and 68Ga-labeled GRPR-antagonist for PET imaging of gastrin-releasing peptide receptor expression in prostate cancer" [Abstract No. OP060, Oral Session Title: Radiopharmaceuticals & Radiochemistry & Dosimetry: PET Radiopharmaceuticals, Sunday, October 20, 11:41 a.m. – 11:52 a.m., Room: Rhône 3A/3B]
  • "SPECT/fluorescence dual-modality imaging of carcinoembryonic antigen-expressing tumors: a pretargeting study" [Abstract No. OP261, Oral Session Title: Featured - Molecular & Multimodality Imaging: Optical Imaging, Monday, October 21, 12:29 p.m. – 12:40 p.m., Room:  Auditorium Pasteur]
  • "A Phase Ιb study of fractionated 90Υ-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer after ≥ 2 prior therapies" [Abstract No. OP670, Oral Session Title: Radionuclide Therapy & Dosimetry: Miscellaneous Therapy, Wednesday, October 23, 8:00 a.m. – 8:11 a.m., Room:  Gratte-Ciel 1/2/3]
  • "Radioimmunotherapy (RAIT) with anti-CD22 90Y-epratuzumab in adults with refractory or relapsed CD22+ ALL: preliminary results of a phase I/II study" [Abstract No. OP675, Oral Session Title: Radionuclide Therapy & Dosimetry: Miscellaneous Therapy, Wednesday, October 23, 8:55 a.m. – 9:06 a.m., Room: Gratte-Ciel 1/2/3]
  • "Pharmacokinetics of yttrium-90-labeled epratuzumab in the consolidation radioimmunotherapy of non-Hodgkin's lymphoma" [Abstract No. P400, Poster Session Title: Therapy & Clinical Trials: Radioisotope Therapy - Miscellaneous, Sunday, October 20, 4:00 p.m. – 4:30 p.m., Room:  Poster Exhibition Area]
  • "Anti-CEA antibody fragments labeled with [ 18F]AlF for PET imaging of CEA-expressing tumors" [Abstract No. PW138, Poster Session Title: Poster Walk 14 - Radiopharmaceuticals & Radiochemistry & Dosimetry: Antibodies & Peptides, Tuesday, October 22, 9:15 a.m. – 9:20 a.m., Room: Poster Exhibition Area]

Finally, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA, from October 19-23, 2013, a poster on "Safety, efficacy, and pharmacokinetics of a new humanized anti-Trop-2 antibody-SN-38 conjugate (IMMU-132) for the treatment of diverse epithelial cancers: Phase I clinical experience" will be presented in Poster Session C: Clinical Trials 3 on Tuesday, October 22, at 12:30 p.m. - 3:00 p.m. in Exhibit Hall C-D.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs